News by subject: TRI

Labcorp, a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc., a complete clinical trials solution integrating technology, are pleased to announce a strategic collaboration to advance decentralized clinical...

Upon approval, cabotegravir would be the first injectable, long-acting therapy in Canada for HIV prevention.Application is supported by data from the pivotal phase IIb/III studies evaluating safety and efficacy of long-acting cabotegravir for...

REGENXBIO Inc. today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January...

A new study, "1,5-Anhydroglucitol: A Novel Biomarker of Adherence in Sodium -Glucose Cotransporter 2 Inhibitors," was published online on December 13, 2023, in Diabetes Care, a journal from the American Diabetes Association. The study was conducted...

Providence Medical Technology, Inc. (PMT), a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, announced that the U.S. Food and Drug Administration (FDA) has cleared its CAVUX® FFS-LX: Lumbar Facet...

ASG Superconductors' (ASG) MgB2 superconducting technology - already in use for energy and medical applications such as the world's only truly open MROpenEVO magnetic resonance imaging (MRI) system - is at the heart of the worldwide innovation...

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces it has submitted an application with the UK's Medicines and Healthcare products...

KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell...

Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain, has announced today that China National Medical Products Administration (NMPA)...

Orrum is proud to announce the first recipient of the Bronze Level Certification in our Center of Excellence (COE) program, HCA Florida Fort Walton-Destin Hospital. This certification is a testament to our dedication to setting high-quality...

Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient has been dosed in the Company's phase 2 clinical trial of...

Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of oral testosterone replacement therapy,...

Injecting neuroblastoma tumors with Zika virus shrank or eliminated those tumors in studies with mice, suggesting that the virus could someday serve as an effective cancer therapy, according to a study led by Nemours Children's Health researchers and...

Investors feature leading brain tumor venture philanthropy funds including the Brain Tumor Investment Fund (BTIF) and The Sontag Innovation The along with MEDA Angels, Varia Ventures and private investors.Investment catalyzed by positive results from...

ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and...

Cala, the bioelectronic medicine leader, today announced the results from multiple clinical studies, further strengthening evidence supporting positive outcomes for patients using Cala TAPS Therapy in ET. A randomized pragmatic trial by CVS Health...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, shares a review of important clinical achievements in 2023 and provides a road map for anticipated catalysts in 2024....

Arkstone Medical Solutions, the leading provider of laboratory infectious disease reporting and proactive antimicrobial stewardship, is excited to embark on a groundbreaking clinical study in collaboration with Laboratorio Clínico Roe in Lima, Peru....

Today, in honor of Cervical Cancer Awareness Month, Teal Health, a women's health company focused on increasing access to cervical cancer screenings in the US, announces the SELF-CERV clinical study, in progress at leading health organizations...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced publication in...

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical...

BioArctic AB's (publ) partner Eisai announced today that Leqembi® (brand name in China: "???", generic name: lecanemab-irmb) has been approved in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD...

Zedsen Limited is pleased to announce its partnership with leading university hospital, Imperial College Healthcare NHS Trust, in its first clinical research study to validate its technology....

Chiesi Farmaceutici S.p.A ("Chiesi Group"), an international, research-focused...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the Biologics License Application (BLA) for...

Last Friday, the Department of Veterans Affairs issued a Request for Applications (RFA) to study the use of FDA-designated Breakthrough Therapies, including MDMA-Assisted Therapy and psilocybin, to treat veterans who suffer from PTSD and depression....

Comprehensive Care Services (CCS) has become the world's largest perfusion provider with the acquisition of German-based Life Systems. This move unites two leaders in perfusion care, expanding global access to top-tier patient services....

GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1...

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 StudyData Base Lock 2H January 2024Topline Data Readout Expected Early 1Q Calendar Year 2024Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC PatientsInterim Analysis Data Readout...

Pulmatrix, Inc. ("Pulmatrix" or the "Company")...

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,400 clinical trials in 2023, and grew sales by 30%...

Shuttle Pharmaceuticals Holdings, Inc. ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II...

PLT Health Solutions, Inc. announced that Slendacor® Weight Management Complex has added to its intellectual property portfolio with a recently granted patent related to new clinical work that studied mechanisms of action behind its weight loss and...

Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new...

? Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis ?  ? Preliminary Unaudited Full...

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated...

Harmony...

Rigel Pharmaceuticals, Inc.  today provided a business update...

On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE) technology to help people with severe diseases, announced positive results of its base editing therapy for...

Aegle Therapeutics Corp., a leader in the development of novel extracellular vesicle ("EV") therapies to treat rare and severe dermatological, including immuno-dermatological,...

Jubilant Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of a first-in-class CoREST (Co-repressor of Repressor Element-1 Silencing Transcription) inhibitor JBI-802 with the dual activity on LSD1 and HDAC6, today...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX945 (dusquetide)...

...

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRDtm) to analyze therapeutic response and...

Compugen Ltd.  a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the...

The Partner of Biosion Inc. (Biosion) , OBI Pharma (4174.TWO), announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2...

Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's...

Akadeum Life Sciences?the global leader in buoyancy-based cell separation technology?has been selected to present on its revolutionary microbubble platform at this year's Biotech Showcase, which is being held from January 8-10 in San Francisco....

The article, titled "Salvage of...